Curriculum Vitae

Full name: Yulong He （何玉龙）

Current position

    Principal Investigator （教授）, Model Animal Research Centre, Nanjing University

E-mail: yhe20005@yahoo.com , yulong.he@nicemice.cn

    Tel: +86 2558641512, +86 13645153714 (mobile) 
 

Date and place of birth:    15.01.67, Nanjing, China 
 

Education（学习经历）

        1999  Ph.D., Molecular Biology / Medicine, University of Cambridge, UK.

        1992  M.Sc., Reproductive Biology, Nanjing Agricultural University, China. 
 

Professional appointments（工作经历）

5.2005-present Principal Investigator （教授）, Model Animal Research Centre, Nanjing University, China.

9.2003-5.2005 Scientist, Molecular / Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Biomedicum Helsinki, University of Helsinki, Finland.

11.2000-8.2003  Postdoctoral Researcher, Molecular / Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Biomedicum Helsinki, University of Helsinki, Finland.

4.1999-11.2000 Research Associate, Department of Pathology, University of Cambridge, UK.

2.1996-9.1996 Visiting Scholar, Department of Obstetrics and Gynaecology, University of Cambridge, UK.

1.1994-1.1996 Lecturer, Department of Animal Science, Nanjing Agricultural University, China.

Membership of scientific society

   Active member, American Association for Cancer Research (AACR, Jun. 2004--present).

   Active member, European Association for Cancer Research (EACR, 2005—present) 
 

Academic activity （研究生培养）

Supervisor of graduate students:

2005-: Huilian Huang

2006-: Fei Zhou, Luqing Zhang, Bo Wang

2007-: Jun Zhang, Wencai Han

2008-: Bin Shen, Caiping Chen

Ad hoc reviewer for Clinical Cancer Research, Cancer Research 
 
 

正在承担的科研项目情况

1. 负责项目：国家自然资金面上项目（2008-2010）

项目名称:   受体酪氨酸激酶Tie1介导的信号途径在淋巴管与血管网络重塑与成熟过程中的作用及机制

      项目批准号：30771069

2. 负责项目：国家自然资金面上项目（2007-2009）

      项目名称：VEGFR-3 信号通路在血液细胞形成及维持过程中的作用

      项目批准号：30671038 
 

3. 参与项目（技术骨干）：科技部重大科学研究计划（2007-2011）

      项目名称：心脏发育与血管发生过程中的信号调控机制研究

      项目批准号：2006CB943500 
 

4. 负责项目：教育部新世纪优秀人才支持计划（2006-2008）

      项目名称：肿瘤血管及淋巴管新生的分子调控机制研究 
 

Recent Publications（近期发表的论文）

IF: impact factor 
 

1. Holopainen T^#, Huang H^#, Kim KE, Zhang L, Zhou F, Li C, Yu J, Wu J, Koh GY, Alitalo K^*, He Y^*(corresponding author). Blockade of Tie signaling suppresses both hematogenous and lymphatic tumor metastasis. 2008 (submitted)

2. Tammela T#, He Y# (co-first author), Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, Ylä-Herttuala S, Alitalo K. Distinct Architecture of Lymphatic Vessels Induced by Chimeric Vascular Endothelial Growth Factor-C/Vascular Endothelial Growth Factor Heparin-Binding Domain Fusion Proteins. Circ Res 100:1468-75 (2007). IF: 9.408

3. Wirzenius M, Tammela M, Uutela M, He Y, Odorisio1 T, Zambruno1 G, Nagy JA, Dvorak HF, Ylä-Herttuala S, Shibuya M and Alitalo K. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med 204:1431-40 (2007). IF: 13.965

4. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. VEGFR-3 mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65:4739-46(2005). IF: 8.649

5. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, Alitalo K, Jooss K. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65:6901-9 (2005). IF: 8.649

6. Bhardwaj S, Roy H, Karpanen T, He Y, Jauhiainen S, Hedman M, Alitalo K, Yla-Herttuala S. Periadventitial angiopoietin-1 gene transfer induces angiogenesis in rabbit carotid arteries. Gene Ther 12:388-94 (2005). IF: 5.293

7. He Y*, Rajantie I*, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P, Alitalo K.    Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res 64:3737-40 (2004). IF: 8.649

8. He Y, Karpanen T and Alitalo K. Role of lymphangiogenic factors in lymphatic tumor metastasis. Biochim Biophys Acta （BBA Review Cancer） 1654:3-12 (2004). IF: 8.395

9. Uutela M, Wirzenius M, Paavonen K, Rajantie I, He Y, Karpanen T, Lohela M, Wiig H, Salven P, Pajusola K, Eriksson U, Alitalo K. PDGF-D induces macrophage recruitment, increased interstitial pressure and blood vessel maturation during angiogenesis. Blood 104:3198-204 (2004). IF: 10.12

10. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94:785-7 (2002). IF: 13.844

11. Charnock-Jones DS, He Y and Smith SK.  Angiogenesis and Vascular Endothelial Growth Factor (VEGF) in Reproduction. In The New Angiotherapy (eds T-P D Fan & E C Kohn), pp.115-128 (2002). Humana Press.

12. Smith SK, He Y, Clark DE, Charnock-Jones DS. Angiogenic growth factor expression in placenta. Semin Perinatol 24, 82-86 (2000). IF: 1.413

13. He Y, Smith SK, Day KA, Clark D, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity.  Mol Endocrinol 13:537-545 (1999). IF: 5.708

14. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, and Charnock-Jones DS. A vascular endothelial growth factor antagonist is produced by the placenta and released into the maternal circulation.  Biol Reprod 59:1540-1548 (1998). IF: 3.646

Patent（专利申请）

Alitalo K, He Y, Tammela T. Heparin binding VEGFR-3 ligands (United States Patent Application, published on February 10, 2005，20050032697).

Alitalo K, Saaristo A, Karkkainen M, Tammela T, Asko-Seljavaara S, Yla-Herttuala S, He Y. Use of VEGF-C or VEGF-D in reconstructive surgery (United States Patent Application, published on February 24, 2005，20050043235). 
 
 

已取得的学术成就 
 

   何玉龙博士1999年于英国剑桥大学获博士学位,之后分别在剑桥大学病理系及芬兰赫尔辛基大学/Ludwig肿瘤研究所做博士后及研究员；主要研究血管与淋巴管的发育调控、以及肿瘤血管/淋巴管生成在肿瘤生长与转移过程中的作用及分子调控机制，取得了一定的成绩。在国际重要刊物包括《JNCI: Journal of the National Cancer Institute》，《Cancer Research》，《Circulation Research》等刊物上发表SCI论文13篇，其中第一作者6篇，参与两项专利申请。有关血管、淋巴管与肿瘤转移方面的研究论文被SCI引用总数达635篇次,其中6篇第一作者论文被SCI引用次数大于400篇次,单篇最高被引用次数达156篇次。 
 

   申请人主要学术成绩包括：

   1）揭示了体内VEGF-A生物活性调控的一个新机制，即VEGF-A受体FLT-1信使RNA不同剪接在调控VEGF-A生物活性上起重要作用（He et al., Mol Endocrinol 1999 13: 537-45; Clark et al., Biol Reprod 1998 59:1540-1548）； 
 

   2）首次证实了抑制肿瘤淋巴管新生能阻断淋巴性肿瘤转移，并进一步阐明了血管内皮细胞生长因子受体-3 介导的淋巴管内皮细胞激活在肿瘤细胞入侵及经淋巴管转移过程中起关键作用（Cancer Research 2005, 第一作者；Biochim Biophys Acta 2004, 第一作者；Journal of the National Cancer Institute 2002, 第一作者）,此研究结果首次为阻断VEGFR-3信号传导能抑制肿瘤淋巴管新生及肿瘤转移到淋巴结的假设提供了直接的实验依据,对于理解肿瘤淋巴性转移的分子调控机制及进一步应用于临床有重要意义

   在《J Natl Cancer Inst》同期配发了由美国哈佛大学Drs.RK Jain & TP Padera掇写的评论文章，“Prevention and treatment of lymphatic metastasis by antilymphangiogenic therapy”（Editorials in J Natl Cancer Inst 2002 94:785-87 by RK Jain & TP Padera）； 
 

   3）利用转基因及基因敲除小鼠模型证实，肿瘤的淋巴管新生源于周围组织的淋巴管内皮细胞，而不是源于骨髓来源的内皮细胞祖细胞（He et al., Cancer Res 2004 64:3737-40）；在上述基础上申请人又研究了肿瘤转移的时相，并证实淋巴管新生是肿瘤细胞入侵淋巴管的必要过程（He et al., Cancer Res 2005 65:4739-46）； 
 

   4）研制了两个具有不同肝素结合活性的重组淋巴管生长因子（Circulation Research 2007,共同第一作者），申请者制备了两个编码不同肝素结合活性的重组VEGF-C。重组VEGF-C由于其具备了肝素结合活性，能诱导更有规则的淋巴管生长，具有重要的临床应用意义，有两项与此研究成果有关的专利正在申请中。